DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
No FDA-approved generic GLP-1 exists in the US. Semaglutide patents expire 2026-2031 by country; US patent through 2031. Compounded preparations are not generics.
There are no FDA-approved generic versions of any GLP-1 medication in the US. Generics require both molecule patent expiration and ANDA approval. Semaglutide US patents expire 2031; tirzepatide US patents extend to 2036+. Compounded semaglutide and tirzepatide are NOT generics — they are pharmacist-compounded preparations operating under different regulatory rules (503A/503B), not FDA-approved finished products.
First US semaglutide generics: not before 2032, given patent landscape and ANDA development timelines. Outside the US, semaglutide is already off-patent in India (Cipla, Sun Pharma launched 2025) and Brazil (EMS launched 2025). These products are not legal to import or sell in the US.
Without generics, prices are anchored to manufacturer direct-pay channels (NovoCare $499/mo, LillyDirect $349-499/mo) and commercial insurance copays. Compounded preparations partly filled the price gap during the shortage years, but as that supply contracts, brand cash-pay channels become the floor.
Editorial summary. Pricing and pipeline reflect public information at the date of last review. Manufacturer cash-pay channels, formulary status, and FDA labels change; confirm before relying on any single source.